Medicinal composition for treating cardio-cerebral vascular disease and its preparing method

A technology for cardiovascular and cerebrovascular diseases and compositions, which is applied in the field of pharmaceutical compositions for the treatment of cardiovascular and cerebrovascular diseases and its preparation. The effect of enhancing cerebral blood flow

Active Publication Date: 2010-05-12
INST OF MEDICINAL PLANT DEV CHINESE ACADEMY OF MEDICAL SCI +1
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Simultaneously, this medicine also exists poor water solubility, the shortcomings such as low bioavailability (utilization rate 10%), cause its curative effect for the treatment of cerebral apoplexy to need to further improve

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for treating cardio-cerebral vascular disease and its preparing method
  • Medicinal composition for treating cardio-cerebral vascular disease and its preparing method
  • Medicinal composition for treating cardio-cerebral vascular disease and its preparing method

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0018] Monomer preparation:

[0019] Extract Pueraria lobata with water or dilute alcohol, concentrate the obtained extract, perform silica gel column chromatography, chloroform-methanol gradient elution, and combine the fractions according to TLC chromatography, and then purify with gel Sephadex LH-20 column to obtain The physical and chemical properties of the following components are as follows:

[0020] 1. Formononetin-7-O-glucoside: molecular formula C 22 h 22 o 9 , white crystals, mp.210-2°C.

[0021] UV lambda max (nm) 256,300 (shoulder).

[0022] 1 HNMRδppm (500MHz, DMSO-d 6 Middle, the same below), 8.38 (1H, s, H-2), 8.04 (1H, d, J=9.0Hz; H-5), 7.14 (1H, d, J=9.0Hz, H-6), 7.21 (1H, s, H-8), 7.50 (2H, d, J=9.0Hz, H-2′, 6′), 6.97 (2H, d, J=9.0Hz, H-3′, 5′), 5.12 (1H, d, J = 7.0Hz, sugar terminal proton), 3.78 (3H, s, OCH 3 ).

[0023] 13 CNMRδppm (125MHz, DMSO-d 6 Middle, the same below), 153.5(C-2), 123.9(C-3), 174.5(C-4), 126.8(C-5), 115.5(C-6), 161.4(C-7...

Embodiment 1

[0069] The preparation of embodiment 1 capsule

[0070] Weigh each component according to the following parts by weight: 5 parts of formononetin-7-O-glucoside, 7 parts of daidzein, 5 parts of 3′-methoxyglycoside puerarin, 49 parts of puerarin, and 2 parts of puerarin B , 19 parts of daidzein-8-C-apirosyl-(1-6)-glucoside, 3 parts of puerarin xyloside, 1 part of daidzein-7,4'-diglucoside, puerarin-4' 3.4 parts of -0-glucoside, 0.4 parts of mephrasin-4'-glucoside, 1 part of 4'-methoxygenistin, 5 parts of 3'-hydroxypuerarin, and 1 part of puerarin C; After the components are uniformly mixed, add (or not add) excipients such as dextrin, starch, sucrose, etc., granulate, dry, mix, and fill capsules to obtain.

Embodiment 2

[0071] The preparation of embodiment 2 oral liquid

[0072] Weigh each component according to the following parts by weight: 4.5 parts of formononetin-7-O-glucoside, 6.7 parts of daidzein, 4.5 parts of 3′-methoxypuerarin, 44 parts of puerarin, and 1.8 parts of puerarin B , 17 parts of daidzein-8-apigenyl-(1-6)-glucoside, 2.7 parts of puerarin xylose sprouts, 0.9 parts of daidzein-7,4'-diglucoside, 3'-hydroxypuerarin 4.5 parts, 3 parts of puerarin-4'-O-glucoside, 0.4 part of mefosine-4'-glucoside, 0.9 part of 4'-methoxygenistin, 0.9 part of puerarin C; Dissolve in sterilized distilled water after mixing evenly, add syrup, preservatives and other auxiliary materials, constant volume, filter, fill, sterilize, and get ready.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a compound medication for treatment of brain and cranial vascular disease and said medication comprises components as follows:onocol -7-O-glucoside 4.5-5.5,daidzin 6.7-8.2 , 3'-methoxy puerarin 4.5-5.5, puerarin 44-54,sissotorin 2.7-3.3,puerarin -4'-O- glucoside 3-3.7, glucoside 0.4-0.5, etc. Said inventive medical compound can be prepared into clinical proper drugs in accordance with means of preparation for convention ones.

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and a preparation method thereof, belonging to the field of traditional Chinese medicine. Background technique [0002] Cerebral stroke is a group of diseases with cerebral ischemia and hemorrhagic injury symptoms as the main clinical manifestations, also known as stroke or cerebrovascular accident, with a very high mortality rate and disability rate, mainly divided into hemorrhagic stroke ( Cerebral hemorrhage or subarachnoid hemorrhage) and ischemic stroke (cerebral infarction, cerebral thrombosis), with cerebral infarction being the most common. Hypertension, atherosclerosis, hyperlipidemia, diabetes, heart disease, congenital cerebrovascular diseases can all cause stroke. [0003] Cerebral stroke has an acute onset and a high mortality rate. It is one of the most important fatal diseases in t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61P9/10A61P9/12
Inventor 陈迪华杜力军斯建勇常琪游保成马楠路振敏潘学清杨林孙保华
Owner INST OF MEDICINAL PLANT DEV CHINESE ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap